Potentiation of magnesium sulfate--induced neuromuscular weakness by gentamicin, tobramycin, and amikacin.
D000293:Adolescent; D000583:Amikacin / Q000494:pharmacology*; D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D004357:Drug Synergism; D005260:Female; D005839:Gentamicins / Q000494:pharmacology*; D006801:Humans; D007231:Infant, Newborn; D007232:Infant, Newborn, Diseases / Q000139:chemically induced* / Q000628:therapy; D007442:Intubation, Intratracheal; D007612:Kanamycin / Q000031:analogs & derivatives*; D008278:Magnesium Sulfate / Q000009:adverse effects*; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D009468:Neuromuscular Diseases / Q000139:chemically induced* / Q000628:therapy; D011817:Rabbits; D012131:Respiratory Insufficiency / Q000139:chemically induced / Q000628:therapy; D014031:Tobramycin / Q000494:pharmacology*
D000900:Anti-Bacterial Agents; D005839:Gentamicins; D007612:Kanamycin; D008278:Magnesium Sulfate; D000583:Amikacin; D014031:Tobramycin